Hepatitis, Hepatitis C, Hepatitis C/ Human Immunodeficiency Virus Coinfection
Conditions
Keywords
Hepatitis C, Cepeginterferon alfa, Peginterferon, Treatment
Brief summary
The purpose of the study is to demonstrate the noninferiority of Algeron in combination with ribavirin compared to PegIntron in combination with ribavirin in treatment of chronic hepatitis C in Human Immunodeficiency Virus-1 infected patients
Detailed description
The course of treatment in both groups shall be 12 weeks, and efficacy analysis, i.e. rate of rapid (after the 4th week) and early (after the 12th week) virologic response will be based on polymerase chain reaction data. For patients with treatment failure after the 12th week the antiviral therapy shall be discontinued. All patients who require further anti-viral treatment will receive a combination treatment with Algeron / PegIntron and ribavirin for another 36 weeks. Sustained virologic response will be assessed 24 weeks after last dose of study treatment.
Interventions
Sponsors
Biocad
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Signed Informed Consent Form. * Chronic hepatitis C (genotypes 1а, 1b, 2, 3, 4) confirmed by positive result of hepatitis C virus ribonucleic acid during \> 6 months before screening visit or accompanied with increase in alanine aminotransferase (ALT) level \> 6 months before screening visit. * Confirmed Human Immunodeficiency Virus-1 infection based on enzyme-linked immunosorbent assay and immune blotting results. * Clinically sustained phase of Human Immunodeficiency Virus-1 infection with absence of active opportunistic Human Immunodeficiency Virus-associated diseases for at least 30 calendar days before inclusion in the study. * Level of CD4+-lymphocytes is not less than 500 cells/mm3 for patients not requiring highly active antiretroviral therapy and which will not be assigned to antiretroviral therapy during the study period. * For patients receiving sustained highly active antiretroviral therapy for not less than 12 weeks and planning to continue comply with this treatment regimen during the following 24 weeks, level of CD4+-lymphocytes ≥300 cells/mm3, Human Immunodeficiency Virus ribonucleic acid ≤50 copies/ml. * Men and women aged 18 to 70 inclusively. * Body mass index in the range of 18 - 30 kg/m2 inclusively . * Preserved protein-synthetizing liver function (International Normalized Ratio \< 1.7, albumin \> 35 g/l). * Absence of signs of hepatic encephalopathy and ascites according to clinical examination and ultrasound examination. * Patients with preserved child-bearing potential and their partners agree to use barrier method of contraception during the whole period of therapy and during 7 months after the treatment completion. * Documentary confirmed results of liver elastography (fibroscan) during last year before enrollment in the study or patient agreement to undergo this examination during screening.
Exclusion criteria
* Intolerance of alfa-interferons, ribavirin or any components of tested drug product based on medical history. * Presence of hepatitis B, A, E markers. * Presence of documentary confirmed clinically significant concurrent liver diseases (alcoholic liver cirrhosis, drug-induced liver cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, non-alcoholic steatohepatitis, biliary cirrhosis etc.). * Past history of Hepatitis C Virus treatment with interferon alfa or pegylated interferon alfa. * For patients receiving sustained highly active antiretroviral therapy - presence of nevirapine, stavudine, zidovudine, didanosine in treatment regimen. * Use of injectable and non-injectable interferons alfa/ interferon inducers for any indication (except for hepatitis C), radiotherapy, cytotoxic chemotherapy for one month prior to inclusion in the study. * Cholestic hepatitis (level of direct bilirubin, alkaline phosphatase, gamma glutamyltransferase, exceeding upper normal limit in \> 5 times). * Decompensated liver cirrhosis confirmed with results of laboratory analyses (Child-Pugh class B, C) or ultrasound examination. * Any documentary confirmed autoimmune diseases (such as Crohn's disease, ulcerative colitis, systemic lupus erythematosus, idiopathic thrombocytopenic purpura, scleroderma, autoimmune hemolytic anemia, severe psoriasis). * Deviations of hematologic (hemoglobin less than lower normal limit; neutrophils \< 1.5 x 10\^9/l; thrombocytes \< 90 x 10\^9/ l) and biochemical (creatinine level \> 1.5 times higher upper normal limit, ALT is \> 10 times higher upper normal limit) parameters. * Documentary confirmed diagnosis of hemoglobinopathy (for example, thalassemia, sickle-cell anemia). * Severe depression, schizophrenia, any other mental disorders which according to the investigator are contraindications for antiviral treatment. * Epilepsy and/or central nervous system disorder. * Disorder of thyroid function (level of thyroid stimulating hormone out of the normal range). * Documentary confirmed or suspected hepatocellular carcinoma based on the results of alfa-fetoprotein (AFP) assay ≥ upper normal limit. * Antinuclear antibodies (ANA) titer measured at screening is not less than 1:640 or documentary confirmed signs of autoimmune hepatitis based on the results of biopsy. * Documentary confirmed malignant neoplasms. * Documentary confirmed lung diseases associated with respiratory failure. * Treatment of Human Immunodeficiency Virus-1 with immunotherapeutic vaccines within 90 days prior to screening. * Necessity in assignment of antimycobacterial therapy. * Pregnancy, lactation period. * Documentary confirmed retinopathy (for example, cytomegalovirus retinitis, macular degeneration). * Severe concurrent diseases (for example, severe arterial hypertension, sever coronary heart disease, heart failure, decompensated diabetes mellitus and other) which are contraindications for antiviral therapy according to the investigator opinion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Early Virological Response | 12 weeks | Proportion of randomized patients achieving early virologic response - negative polymerase chain reaction result for Hepatitis C Virus ribonucleic acid (\< 15 IU/ml) or ≥ 2log10 decrease of viral load after 12 weeks of study treatment |
| Early Virological Response in Patients With Different Hepatitis C Virus Genotypes | 12 weeks | Proportion of randomized patients with different Hepatitis C Virus (HCV) genotypes achieving early virologic response - negative polymerase chain reaction result for HCV ribonucleic acid (\< 15 IU/ml) or ≥ 2log10 decrease of viral load after 12 weeks of study treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rapid Virological Response | 4 weeks | Proportion of randomized patients achieving rapid virologic response - negative polymerase chain reaction result for Hepatitis C Virus ribonucleic acid (\< 15 IU/ml) after 4 weeks of treatment |
| Rapid Virological Response in Patients With Different Hepatitis C Virus Genotypes | 4 weeks | Proportion of randomized patients with different Hepatitis C Virus (HCV) genotypes achieving rapid virological response - negative polymerase chain reaction result for HCV ribonucleic acid (\< 15 IU/ml) after 4 weeks of treatment |
| Viral Breakthrough | screening data and at 4 or 12 weeks of treatment. | Proportion of patients in each groups with level of Hepatitis C Virus ribonucleic acid \> 15 IU/ml after Hepatitis C Virus ribonucleic acid was not present or Hepatitis C Virus ribonucleic acid was increased by more than 1log10 from baseline at 4 or 12 weeks of treatment |
| Biochemical Response | 12 weeks | Proportion of patients in each group with alanine aminotransferase level ≤ upper normal limit after 12 weeks of therapy |
Countries
Russia
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Algeron Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight \<65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight \> 105 kg)
Algeron: 1.5 µg/kg of body weight subcutaneously, once a week | 70 |
| PegIntron PegIntron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight \<65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight \> 105 kg).
PegIntron: 1.5 µg/kg of body weight subcutaneously, once a week | 70 |
| Total | 140 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 0 | 2 |
| Overall Study | Withdrawal by Subject | 3 | 1 |
Baseline characteristics
| Characteristic | Algeron | Total | PegIntron |
|---|---|---|---|
| Age, Continuous | 33 years | 33.5 years | 34 years |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants | 3 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 68 Participants | 137 Participants | 69 Participants |
| Region of Enrollment Russian Federation | 70 participants | 140 participants | 70 participants |
| Sex: Female, Male Female | 25 Participants | 49 Participants | 24 Participants |
| Sex: Female, Male Male | 45 Participants | 91 Participants | 46 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 70 / 70 | 69 / 71 |
| serious Total, serious adverse events | 0 / 70 | 2 / 71 |
Outcome results
Primary
Early Virological Response
Proportion of randomized patients achieving early virologic response - negative polymerase chain reaction result for Hepatitis C Virus ribonucleic acid (\< 15 IU/ml) or ≥ 2log10 decrease of viral load after 12 weeks of study treatment
Time frame: 12 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Algeron | Early Virological Response | 90.0 percentage of patients |
| PegIntron | Early Virological Response | 81.4 percentage of patients |
p-value: 0.227Fisher Exact
Primary
Early Virological Response in Patients With Different Hepatitis C Virus Genotypes
Proportion of randomized patients with different Hepatitis C Virus (HCV) genotypes achieving early virologic response - negative polymerase chain reaction result for HCV ribonucleic acid (\< 15 IU/ml) or ≥ 2log10 decrease of viral load after 12 weeks of study treatment
Time frame: 12 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Algeron | Early Virological Response in Patients With Different Hepatitis C Virus Genotypes | 82.4 percentage of patients |
| PegIntron | Early Virological Response in Patients With Different Hepatitis C Virus Genotypes | 97.2 percentage of patients |
| PegIntron - HCV-1 | Early Virological Response in Patients With Different Hepatitis C Virus Genotypes | 75.8 percentage of patients |
| PegIntron - HCV-2/3 | Early Virological Response in Patients With Different Hepatitis C Virus Genotypes | 88.5 percentage of patients |
Secondary
Biochemical Response
Proportion of patients in each group with alanine aminotransferase level ≤ upper normal limit after 12 weeks of therapy
Time frame: 12 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Algeron | Biochemical Response | 68.6 percentage of patients |
| PegIntron | Biochemical Response | 82.9 percentage of patients |
Secondary
Rapid Virological Response
Proportion of randomized patients achieving rapid virologic response - negative polymerase chain reaction result for Hepatitis C Virus ribonucleic acid (\< 15 IU/ml) after 4 weeks of treatment
Time frame: 4 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Algeron | Rapid Virological Response | 51.4 percentage of patients |
| PegIntron | Rapid Virological Response | 37.1 percentage of patients |
p-value: >0.05Fisher Exact
Secondary
Rapid Virological Response in Patients With Different Hepatitis C Virus Genotypes
Proportion of randomized patients with different Hepatitis C Virus (HCV) genotypes achieving rapid virological response - negative polymerase chain reaction result for HCV ribonucleic acid (\< 15 IU/ml) after 4 weeks of treatment
Time frame: 4 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Algeron | Rapid Virological Response in Patients With Different Hepatitis C Virus Genotypes | 23.5 percentage of patients |
| PegIntron | Rapid Virological Response in Patients With Different Hepatitis C Virus Genotypes | 77.8 percentage of patients |
| PegIntron - HCV-1 | Rapid Virological Response in Patients With Different Hepatitis C Virus Genotypes | 21.2 percentage of patients |
| PegIntron - HCV-2/3 | Rapid Virological Response in Patients With Different Hepatitis C Virus Genotypes | 51.4 percentage of patients |
Secondary
Viral Breakthrough
Proportion of patients in each groups with level of Hepatitis C Virus ribonucleic acid \> 15 IU/ml after Hepatitis C Virus ribonucleic acid was not present or Hepatitis C Virus ribonucleic acid was increased by more than 1log10 from baseline at 4 or 12 weeks of treatment
Time frame: screening data and at 4 or 12 weeks of treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Algeron | Viral Breakthrough | 0 percentage of patients |
| PegIntron | Viral Breakthrough | 0 percentage of patients |